GeekWire August 14, 2024
Charlotte Schubert

In a laboratory near downtown Seattle on the shores of Lake Union, Hetu Kamisetty is helping build what he says is the biotech company of the future.

If talent, money and novel technology are any indication, he and his colleagues have a good shot at it.

Kamisetty heads the Seattle location of Xaira Therapeutics, an AI-focused startup launched in April with more $1 billion from investors.

The lab is populated by researchers skimmed from the nearby Institute for Protein Design, the lauded University of Washington research hub and spinout machine.

The founding members of Xaira’s molecule design and AI team, which Kamisetty leads, are all IPD alums.

Nathaniel Bennett helped develop RFDiffusion, an AI-powered tool from the IPD used to...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Sun Pharma buys Checkpoint and its new cancer drug
3 ways to accelerate development and de-risk cell and gene therapy manufacturing
FDA OKs First Gene Therapy Implant for a Rare Eye Disease
Anna Greka: Molecular Sleuthing for Rare Diseases
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Share This Article